CDK4 and breast carcinoma: We reported the experience of the EADV task force “dermatology for cancer patients” who examined the largest case series regarding the spectrum of skin toxicities recorded in breast cancer patients undergoing treatment with CDK4/6i, including each of the approved and available CDK4/6i.